HALEON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 329.9 GBX | +0.40% |
|
-1.35% | +2.56% |
| May. 03 | GSK plc : Back on track |  |
| May. 02 | Deutsche Bank likes TP ICAP but says sell CMC | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 11.45B 14.36B | Sales 2025 * | 11.93B 14.97B | Capitalization | 30.13B 37.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.46B 1.83B | Net income 2025 * | 1.69B 2.12B | EV / Sales 2024 * | 3.31 x |
| Net Debt 2024 * | 7.81B 9.8B | Net Debt 2025 * | 7.07B 8.87B | EV / Sales 2025 * | 3.12 x |
| P/E ratio 2024 * |
20.6
x | P/E ratio 2025 * |
17.9
x | Employees | 25,408 |
| Yield 2024 * |
1.87% | Yield 2025 * |
2.16% | Free-Float | 77.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haleon plc
| 1 day | +0.40% | ||
| 1 week | -1.35% | ||
| Current month | -2.83% | ||
| 1 month | +1.23% | ||
| 3 months | +0.26% | ||
| 6 months | +2.97% | ||
| Current year | +2.56% |
1 week
326.10
341.30
1 month
319.20341.30
Current year
308.37342.15
1 year
306.80350.50
3 years
241.17357.65
5 years
241.17357.65
10 years
241.17357.65
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McNamara
CEO | Chief Executive Officer | 57 | 21-07-21 |
Tobias Hestler
DFI | Director of Finance/CFO | 52 | 21-11-30 |
Franck Riot
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bryan Supran
BRD | Director/Board Member | - | 22-07-17 |
Dame Cox
BRD | Director/Board Member | 64 | 22-07-17 |
Tracy Clarke
BRD | Director/Board Member | 57 | 22-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 148 M€ | +9.14% | - | |
| 0.99% | 11 M€ | +0.83% | - | |
| 0.94% | 5 M€ | +9.66% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 329.9 | +0.40% | 31,717,290 |
| 24-05-02 | 328.6 | -0.73% | 18,083,380 |
| 24-05-01 | 331 | -2.50% | 25,080,210 |
| 24-04-30 | 339.5 | +2.48% | 28,100,380 |
| 24-04-29 | 331.3 | -0.93% | 20,890,900 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:
- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;
- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;
- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;
- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;
- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.299
GBP
Average target price
3.62
GBP
Spread / Average Target
+9.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.56% | 37.81B | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- HLN Stock